Department of Orthopedics, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, 899 Pinghai Road, Suzhou, Jiangsu, 215031, PR China.
Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025, PR China.
Biomaterials. 2024 Apr;306:122475. doi: 10.1016/j.biomaterials.2024.122475. Epub 2024 Jan 25.
Although tumor-infiltrating T lymphocytes (TIL-Ts) play a crucial role in solid tumor immunotherapy, their clinical application has been limited because of the immunosuppressive microenvironment. Herein, we developed an injectable hydrogel microsphere-integrated training court (MS-ITC) to inspire the function of TIL-Ts and amplify TIL-Ts, through grafting with anti-CD3 and anti-CD28 antibodies and bovine serum albumin nanoparticles encapsulated with IL-7 and IL-15. MS-ITC provided the T-cell receptor and co-stimulatory signals required for TIL-Ts activation and IL-7/IL-15 signals for TIL-Ts expansion. Afterward, the MS-ITC was injected locally into the osteosarcoma tumor tissue in mice. MS-ITC suppressed the growth of primary osteosarcoma by more than 95 %, accompanied with primed and expanded TIL-Ts in the tumor tissues, compromising significantly increased CD8 T and memory T cells, thereby enhancing the anti-tumor effect. Together, this work provides an injectable hydrogel microsphere-integrated training platform capable of inspiring TIL-Ts potential for a range of solid tumor immunotherapy.
尽管肿瘤浸润性 T 淋巴细胞(TIL-Ts)在实体瘤免疫治疗中发挥着至关重要的作用,但由于免疫抑制微环境,其临床应用受到限制。在此,我们开发了一种可注射的水凝胶微球集成训练场(MS-ITC),通过与抗 CD3 和抗 CD28 抗体以及包被 IL-7 和 IL-15 的牛血清白蛋白纳米颗粒接枝,来激发 TIL-Ts 的功能并扩增 TIL-Ts。MS-ITC 为 TIL-Ts 的激活提供了 T 细胞受体和共刺激信号,为 TIL-Ts 的扩增提供了 IL-7/IL-15 信号。随后,将 MS-ITC 局部注射到小鼠骨肉瘤肿瘤组织中。MS-ITC 抑制了原发性骨肉瘤的生长,超过 95%,同时在肿瘤组织中引发和扩增了 TIL-Ts,显著增加了 CD8 T 和记忆 T 细胞,从而增强了抗肿瘤效果。总之,这项工作提供了一种可注射的水凝胶微球集成训练平台,能够激发 TIL-Ts 的潜力,用于多种实体瘤免疫治疗。